{"id":"W4390743174","doi":"10.1007/s40120-023-00565-7","title":"Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Greenwich Biosciences; EMD Serono; Genentech; Horizon Therapeutics; Mylan; TG Therapeutics; Biogen; Celgene; Sanofi Genzyme; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Jazz Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; Sanofi; MedDay Pharmaceuticals; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Multiple sclerosis; Neurology; Clinical trial; Immunosuppression; Disease; Interferon beta; Interferon beta-1a; Glatiramer acetate; Internal medicine; Oncology; Pediatrics; Immunology; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001817389,0.0001233357,0.0003261043,0.0001247261,0.00005221457,0.00001339609,0.00007048983,0.00009538038,0.00003856128],"category_scores_gemma":[0.0000884401,0.0001003684,0.0001180518,0.00008574378,0.0003590272,0.00004738864,0.00004130131,0.0002305142,0.00000452064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000007840848,"about_ca_system_score_gemma":0.00005098341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000354898,"about_ca_topic_score_gemma":0.000007589414,"domain_scores_codex":[0.9990788,0.00007757603,0.0001835727,0.0003387319,0.0001175445,0.0002038523],"domain_scores_gemma":[0.998961,0.0006942979,0.00003216834,0.0001690756,0.00007728001,0.0000661931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.06496702,0.00128323,0.05959417,0.0008749189,0.003074796,0.0004855217,0.02051056,0.00000780179,0.377492,0.002136089,0.01244298,0.457131],"study_design_scores_gemma":[0.02551061,0.06746206,0.6887106,0.0006852401,0.0002045495,0.0005274339,0.003210604,0.006417342,0.03465126,0.001248269,0.1704907,0.0008813661],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9668337,0.02855828,0.00006292469,0.003255173,0.0002036176,0.0006693348,0.00004617142,0.00007379121,0.0002970735],"genre_scores_gemma":[0.9887558,0.01041244,0.00006722417,0.0004234886,0.0001177625,0.00008261344,0.000006861347,0.00002550319,0.0001082677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6291164,"threshold_uncertainty_score":0.4092903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09876984893684974,"score_gpt":0.322607626696812,"score_spread":0.2238377777599623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}